TPTX News and Press, Turning Point Therapeutics Inc. From 02/15/22

The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...

If you believe in the January Barometer theory -- that returns in the first month of the year are a bellwether for performance for the rest of the year -- then biotech investors better buckle their seatbelts. The iShares Nasdaq Biotechnology ETF (IBB +1.2%) finished off last month with a ...

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearance from the FDA for the company’...

Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated NSCLC cohort TRIDENT-1 topline BICR ORR and DOR data from ROS1+ NSCLC cohorts and pre-NDA discussion anticipat...

MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors...

SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced regulatory updates for its lead drug candidate, repotrectinib, a ROS1/TRK In...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

After peaking at over $141 in February 2021, shares of Turning Point Therapeutics, Inc. had lost 55% of their value through early October, largely due to a data vacuum. That silence was broken on October 7, 2021, with solid, yet short-of-expectations results for its lead candidate (re...

The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Turning Point Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation

Turning Point Therapeutics, Inc. (TPTX) Q3 2021 Results Earnings Conference Call November 10, 2021, 04:30 PM ET Company Participants Adam Levy - Senior Vice President of Investor Relations Athena Countouriotis - President and Chief Executive Officer Paolo Tombesi - Executive Vice President an...